Yevgeniya S Kushchayeva1, Sergiy V Kushchayev2, Megan Startzell1, Elaine Cochran1, Sungyoung Auh1, Yuhai Dai3, Marissa Lightbourne4, Monica Skarulis1, Rebecca J Brown1. 1. Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health, Bethesda, Maryland. 2. Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland. 3. Clinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health, Bethesda, Maryland. 4. National Institute of Child Health and Human Development/National Institutes of Health, Bethesda, Maryland.
Abstract
CONTEXT: Insulin and leptin may increase growth and proliferation of thyroid cells, underlying an association between type 2 diabetes and papillary thyroid cancer (PTC). Patients with extreme insulin resistance due to lipodystrophy or insulin receptor mutations (INSR) are treated with high-dose insulin and recombinant leptin (metreleptin), which may increase the risk of thyroid neoplasia. OBJECTIVE: The aim of this study was to analyze thyroid structural abnormalities in patients with lipodystrophy and INSR mutations and to assess whether insulin, IGF-1, and metreleptin therapy contribute to the thyroid growth and neoplasia in this population. DESIGN: Thyroid ultrasound characteristics were analyzed in 81 patients with lipodystrophy and 11 with INSR (5 homozygous; 6 heterozygous). Sixty patients were taking metreleptin. RESULTS: The prevalence of thyroid nodules in children with extreme insulin resistance (5 of 30, 16.7%) was significantly higher than published prevalence for children (64 of 3202; 2%), with no difference between lipodystrophy and INSR. Body surface area-adjusted thyroid volume was larger in INSR homozygotes vs heterozygotes or lipodystrophy (10.4 ± 5.1, 3.9 ± 1.5, and 6.2 ± 3.4 cm2, respectively. Three patients with lipodystrophy and one INSR heterozygote had PTC. There were no differences in thyroid ultrasound features in patients treated vs not treated with metreleptin. CONCLUSION: Children with extreme insulin resistance had a high prevalence of thyroid nodules, which were not associated with metreleptin treatment. Patients with homozygous INSR mutation had thyromegaly, which may be a novel phenotypic feature of this disease. Further studies are needed to determine the etiology of thyroid abnormalities in patients with extreme insulin resistance. Published by Oxford University Press on behalf of the Endocrine Society 2019.
CONTEXT: Insulin and leptin may increase growth and proliferation of thyroid cells, underlying an association between type 2 diabetes and papillary thyroid cancer (PTC). Patients with extreme insulin resistance due to lipodystrophy or insulin receptor mutations (INSR) are treated with high-dose insulin and recombinant leptin (metreleptin), which may increase the risk of thyroid neoplasia. OBJECTIVE: The aim of this study was to analyze thyroid structural abnormalities in patients with lipodystrophy and INSR mutations and to assess whether insulin, IGF-1, and metreleptin therapy contribute to the thyroid growth and neoplasia in this population. DESIGN: Thyroid ultrasound characteristics were analyzed in 81 patients with lipodystrophy and 11 with INSR (5 homozygous; 6 heterozygous). Sixty patients were taking metreleptin. RESULTS: The prevalence of thyroid nodules in children with extreme insulin resistance (5 of 30, 16.7%) was significantly higher than published prevalence for children (64 of 3202; 2%), with no difference between lipodystrophy and INSR. Body surface area-adjusted thyroid volume was larger in INSR homozygotes vs heterozygotes or lipodystrophy (10.4 ± 5.1, 3.9 ± 1.5, and 6.2 ± 3.4 cm2, respectively. Three patients with lipodystrophy and one INSR heterozygote had PTC. There were no differences in thyroid ultrasound features in patients treated vs not treated with metreleptin. CONCLUSION:Children with extreme insulin resistance had a high prevalence of thyroid nodules, which were not associated with metreleptin treatment. Patients with homozygous INSR mutation had thyromegaly, which may be a novel phenotypic feature of this disease. Further studies are needed to determine the etiology of thyroid abnormalities in patients with extreme insulin resistance. Published by Oxford University Press on behalf of the Endocrine Society 2019.
Authors: P A van den Brandt; D Spiegelman; S S Yaun; H O Adami; L Beeson; A R Folsom; G Fraser; R A Goldbohm; S Graham; L Kushi; J R Marshall; A B Miller; T Rohan; S A Smith-Warner; F E Speizer; W C Willett; A Wolk; D J Hunter Journal: Am J Epidemiol Date: 2000-09-15 Impact factor: 4.897
Authors: L Shefi-Friedman; E Wertheimer; S Shen; A Bak; D Accili; S R Sampson Journal: Am J Physiol Endocrinol Metab Date: 2001-07 Impact factor: 4.310
Authors: S Deleu; I Pirson; K Coulonval; A Drouin; M Taton; F Clermont; P P Roger; T Nakamura; J E Dumont; C Maenhaut Journal: Mol Cell Endocrinol Date: 1999-03-25 Impact factor: 4.102
Authors: Paula Juiz-Valiña; María Cordido; Elena Outeiriño-Blanco; Sonia Pértega; Bárbara María Varela-Rodríguez; María Jesús García-Brao; Enrique Mena; Lara Pena-Bello; Susana Sangiao-Alvarellos; Fernando Cordido Journal: J Clin Med Date: 2020-01-28 Impact factor: 4.241
Authors: María Cordido; Paula Juiz-Valiña; Paula Urones; Susana Sangiao-Alvarellos; Fernando Cordido Journal: J Clin Med Date: 2022-02-28 Impact factor: 4.241